Overview | Management & Treatment | Newsletter Signup | Join Community
Drug Payment Assistance Programs for Rheumatoid & Psoriatic Arthritis
Simponi®(golimumab)is one of five marketed TNF inhibitors(TNFi) that is FDA approved for use in psoriatic arthritis(PsA)
Doctors evaluated mobility, self-care, and activities of daily living in Cosentyx treated patients.
Itching can be relieved by the easily available Z and Z OTC medication combination.
Dual Inhibition of IL-17 appears promising for treatment of PsA according to University of Rochester led clinical trial
ACR recommends TNF biologic and "treat to target" approach for all individuals with Psoriatic Arthritis.